🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The financial burden of a breast cancer diagnosis can be overwhelming, even if you have health insurance. Thank you Breastcancer.org for bringing attention to this important issue! breastcancer.org/managing-life/…

Answer an age old question: StViateurBagel or Fairmount Bagel 🥯? Let us know what you think👇 #mtl #montreal

Scientists, don’t let your writing resemble something you pulled out of your bot science.org/content/articl…

Ever wondered how long it takes to reformat papers for journal submissions? We did, and decided to write about it! We calculated time and money lost, interviewed journal editors and researchers, and developed some new guideline propositions. Read here: bmcmedicine.biomedcentral.com/articles/10.11…

Is a Revolution in Cancer Treatment Within Reach? nytimes.com/2023/06/16/opi…

Dr. Joshua Press co-authors a plain-language summary of ground-breaking research of immunotherapy research for endometrial cancer performed in part Providence Swedish Cancer Institute Research #garnet 💍 #dostarlimab #immunotherapy doi.org/10.2217/fon-20…

Check out the writing acknowledgement at the end! 😉 A Plain Language Summary of Results from the GARNET Study of Dostarlimab in Patients with Endometrial Cancer | Future Oncology futuremedicine.com/doi/10.2217/fo…

DNA sequencing improves cancer treatment but remains underused. Why? usatoday.com/story/news/hea…

Study on phase I trial efficacy and safety of #dostarlimab in patients with advanced or recurrent #EndometrialCancer and analysis of tumor #biomarkers as prognostic indicators by Oaknin et al. bit.ly/44nqTTn Cara Mathews Valentina Boni Susana Banerjee AACR

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study | Clinical Cancer Research | American Association for Cancer Research aacrjournals.org/clincancerres/…

So happy to see this published! Increasing Clinical Trial Participation of Black Women Diagnosed with Breast Cancer pubmed.ncbi.nlm.nih.gov/37314691/

❣️ Just released, a look into Vemurafenib and Obinutuzumab as frontline treatment for Hairy Cell Leukemia. A study years in the making, read here: evidence.nejm.org/doi/full/10.10…. #ThisIsBloodCancer

Designing Best-in-Class Small Molecules needs to integrate advances in Chemistry, Cancer Biology, & Data Science. Responses rates and prevalence across actionable targets is nicely summarized in this paper. doi.org/10.1158/2159-8…

Finding Endometrial Cancer Subtypes With Universal Testing With NGS medpagetoday.com/reading-room/a…

Resmetirom has just become the first drug for the liver disease NASH (also known as MASH) to gain FDA approval. Read about this advance and the pipeline of drugs such as FGF21 analogues, PPAR modulators, GLP1 agonists and oligonucleotide drugs here bit.ly/48StoyM (free)

Phase 1b trial of gedatolisib (IV dual PI3K–mTOR inh) + palbo + ET for HR+ MBC out on The Lancet Oncology (n=103). ORR ranging between 25-85% depending on prior treatments. Non-negligible toxicities, with 89% stomatitis, 77% nausea, 76% neutropenia, 52% rash. thelancet.com/journals/lanon…

NEW Results from the dose expansion groups of an open-label, phase 1b study of gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer. #bcsm thelancet.com/journals/lanon…

Back by popular demand! The #MetGala as things seen in science… First up, Cynthia Erivo as dark field microscopy blood cells:

National Comprehensive Cancer Network (NCCN) now includes #universal #germline #genetictesting for all #patients w/ #endometrialcancer/#uterinecancer c/w gynecologiconcology-online.net/article/S0090-…… @GynOncJnls Elsevier Invitae Labcorp i.e. recommends #germlinetesting for all #patients w/ #CRC or #EC <50, consider

The next big thing in sequencing is coming. And it’s small. Learn more at our virtual event on October 9 at 9 a.m. PT: bit.ly/3NdvvVb